BCR/ABL1 Fusion Transcript, t(9;22)(q34;q11.2), RT-PCR

BCR/ABL1 Fusion Transcript, t(9;22)(q34;q11.2), RT-PCR
WSLH Department: Cytogenetics
WSLH Test Code:887M31
Includes:Reverse-Transcription PCR for the detection of Major (p210) and minor (p190) BCR/ABL1 fusion transcripts associated with t(9;22)(q34;q11.2) recurrent in CML and ALL.
Methodology:Qualitative Reverse-Transcription PCR
Availability:Monday-Friday 7:45 AM - 4:30 PM, Saturday 7:45 AM - 12:00 PM
Turn-around Time:Approximately 2-4 days. (Reports are issued Monday-Friday 7:45 AM - 4:30 PM)
Recommended Uses:Detection of BCR/ABL1 fusion transcripts associated with CML and ALL. Aid in diagnosis of hematologic disorders.
Specimen Requirements:**0.5-1.0 ml early aspirate bone marrow OR **5-10 ml whole blood collected in EDTA vacuum type tube
Collection Kit/Container: 
Patient Preparation: 
Collection Instructions:**Bone marrow: 1.0-2.0ml bone marrow from the first or second aspirate. It is important that material submitted for cytogenetic analysis is from an early aspirate. Later aspirates are likely to be diluted with blood and the abnormal clone may not be detected. Transfer the marrow to a sterile, EDTA vacuum type tube for delivery to State Lab. **Blood: Draw blood using aseptic techniques into a sterile EDTA vacuum type tube(s). Invert tube(s) to mix. If using larger tubes, draw full tube(s) of blood to avoid over-treatment with anti-coagulant.
Specimen Handling and Transport:Store and transport specimens at room temperature (may transport with coolant during hot, >85 degrees, weather). Specimens must be received by the laboratory within 24 hours of collection.
Unacceptable Conditions:Sample must not be frozen or hemolyzed. Please note that sodium heparin is known to inhibit PCR. Plasma and serum are not acceptable.
Requisition Form:Cytogenetics Lab Neoplasia Diagnosis Form #132
Required Information:Laboratory regulations require the following minimum information to be provided on the requisition form for a specimen to be accepted for testing: Patient name or unique identifier; date and time of collection, patient date of birth and sex, specimen type/site of collection, test request(s), reason for referral, clinician name and UPIN/NPI, and address for reporting results. Please be certain that name/identifier on the form matches that on the specimen label.
Results include:BCR/ABL1 fusion detected/not detected. Splice breakpoints reported.
Limitations:This assay is designed to detect six major (p210) and four minor (p190) BCR-ABL1 fusion transcripts. Rare BCR-ABL1 fusions involving other breakpoints are not detectable by this test. This assay will not detect BCR-ABL1 fusion gene transcripts below the limit of detection (LOD). The analytical sensitivity (LOD) of this assay has been determined at 1 BCR-ABL1 positive cell in 1,000 cells, or 0.1%. This test is not intended to detect minimal residual disease. Failure to identify an abnormal clone by RT-PCR does not rule out the presence of other abnormalities in the specimen.
Additional Tests Recommended: 
Additional Comments: 
Additional Tests Performed: 

Back to test list


Search Again